Biogen expands immunology portfolio

US biotech major Biogen (Nasdaq: BIIB) and Chicago, Canada-based Vanqua Bio today announced a license agreement granting Biogen exclusive worldwide rights to Vanqua’s pre-clinical, oral C5aR1 antagonist.

Biogen noted that this agreement strengthens its immunology strategy by advancing a proven immune mechanism with the potential to address a broad range of inflammatory disorders with high unmet need.

“This agreement reflects our strong commitment to building a comprehensive immunology pipeline with a strategic focus on both innate and adaptive immune pathways,” said Jane Grogan, executive vice president and head of research at Biogen. “C5aR1 is a well-validated target involved in neutrophil-mediated inflammation, which plays a central role across a range of inflammatory disorders. Advancing this program enables us to deepen our scientific and clinical focus in immunological diseases where we believe Biogen can make a meaningful difference for patients,” she added.